(GMAB) Genmab - CO
Sector: Healthcare | Industry: Biotechnology | Exchange: CO (Denmark) | Market Cap: 96.449m DKK | Total Return: 17.2% in 12m
Avg Turnover: 247M
EPS Trend: 76.7%
Qual. Beats: 0
Rev. Trend: -64.2%
Qual. Beats: 0
Warnings
Beneish M-Score -1.44 > -1.5 - likely earnings manipulation
Below Avwap Earnings
Tailwinds
No distinct edge detected
Genmab A/S is a Denmark-based biotechnology company specializing in the development of antibody-based therapies for oncology and other chronic diseases. The company’s commercial portfolio includes EPKINLY and Tivdak, targeting large B-cell lymphoma and metastatic cervical cancer. Its pipeline extends into treatments for solid tumors, non-small cell lung cancer, and various hematological malignancies.
The company operates under a partnership-heavy business model, leveraging collaboration agreements with major pharmaceutical entities including AbbVie, Pfizer, and Johnson & Johnson to co-develop and commercialize its proprietary technology platforms. This strategy allows biotechnology firms to mitigate the high capital expenditures and clinical trial risks inherent in drug development by sharing costs and infrastructure with established industry leaders.
Genmab generates significant revenue through royalty streams and milestone payments from licensed products such as DARZALEX for multiple myeloma and Kesimpta for multiple sclerosis. In the biotechnology sector, intellectual property and proprietary platforms-such as Genmab’s DuoBody and HexaBody technologies-serve as the primary drivers of long-term valuation by enabling the creation of bispecific antibodies with enhanced therapeutic precision.
- Darzalex royalty revenue growth sustains core cash flow and R&D funding
- Epcoritamab market share expansion in DLBCL and follicular lymphoma segments
- Profitable pipeline progression through high-value strategic partnerships with AbbVie and J&J
- Acquisition of ProfoundBio accelerates antibody-drug conjugate portfolio diversification and scaling
| Net Income: 820.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -89.29 > 1.0 |
| NWC/Revenue: 14.83% < 20% (prev 18.10%; Δ -3.27% < -1%) |
| CFO/TA 0.07 > 3% & CFO 904.1m > Net Income 820.3m |
| Net Debt (3.97b) to EBITDA (1.37b): 2.90 < 3 |
| Current Ratio: 2.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.9m) vs 12m ago -0.12% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 99.20% > 50% (prev 275.3%; Δ -176.1% > 0%) |
| Interest Coverage Ratio: 7.72 > 6 (EBIT TTM 1.28b / Interest Expense TTM 166.5m) |
| A: 0.11 (Total Current Assets 2.57b - Total Current Liabilities 1.18b) / Total Assets 12.4b |
| B: 0.33 (Retained Earnings 4.09b / Total Assets 12.4b) |
| C: 0.14 (EBIT TTM 1.28b / Avg Total Assets 9.47b) |
| D: 0.85 (Book Value of Equity 5.68b / Total Liabilities 6.69b) |
| Altman-Z'' = 3.62 = AA |
| DSRI: 2.49 (Receivables 1.03b/799.0m, Revenue 9.40b/18.1b) |
| GMI: 0.98 (GM 95.35% / 97.23%) |
| AQI: 2.23 (AQ_t 0.77 / AQ_t-1 0.35) |
| SGI: 0.52 (Revenue 9.40b / 18.1b) |
| TATA: -0.01 (NI 820.3m - CFO 904.1m) / TA 12.4b) |
| Beneish M = -1.44 (Cap -4..+1) = D |
As of June 20, 2026, the stock is trading at DKK 1627.00 with a total of 119,475 shares traded.
Over the past week, the price has changed by +0.12%,
over one month by -4.17%,
over three months by -2.24% and
over the past year by +17.21%.
Genmab has no consensus analysts rating.
P/E Trailing = 18.5259
P/E Forward = 14.5138
P/S = 24.7242
P/B = 2.6727
P/EG = 1.636
Revenue TTM = 9.40b DKK
EBIT TTM = 1.28b DKK
EBITDA TTM = 1.37b DKK
Long Term Debt = 4.93b DKK (from longTermDebt, last quarter)
Short Term Debt = 292.7m DKK (from shortTermDebt, last quarter)
Debt = 5.49b DKK (from shortLongTermDebtTotal, last quarter) + Leases 143.0m
Net Debt = 3.97b DKK (calculated: Debt 5.49b - CCE 1.52b)
Enterprise Value = 100b DKK (96.4b + Debt 5.49b - CCE 1.52b)
Interest Coverage Ratio = 7.72 (Ebit TTM 1.28b / Interest Expense TTM 166.5m)
EV/FCF = 114.9x (Enterprise Value 100b / FCF TTM 873.9m)
FCF Yield = 0.87% (FCF TTM 873.9m / Enterprise Value 100b)
FCF Margin = 9.30% (FCF TTM 873.9m / Revenue TTM 9.40b)
Net Margin = 8.73% (Net Income TTM 820.3m / Revenue TTM 9.40b)
Gross Margin = unknown ((Revenue TTM 9.40b - Cost of Revenue TTM 260.5m) / Revenue TTM)
Tobins Q-Ratio = 8.12 (Enterprise Value 100b / Total Assets 12.4b)
Interest Expense / Debt = 3.03% (Interest Expense 166.5m / Debt 5.49b)
Taxrate = 20.60% (212.8m / 1.03b)
NOPAT = 1.02b (EBIT 1.28b * (1 - 20.60%))
Current Ratio = 2.18 (Total Current Assets 2.57b / Total Current Liabilities 1.18b)
Debt / Equity = 0.97 (Debt 5.49b / totalStockholderEquity, last quarter 5.68b)
Debt / EBITDA = 2.90 (Net Debt 3.97b / EBITDA 1.37b)
Debt / FCF = 4.55 (Net Debt 3.97b / FCF TTM 873.9m)
Total Stockholder Equity = 5.64b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.66% (Net Income 820.3m / Total Assets 12.4b)
RoE = 14.53% (Net Income TTM 820.3m / Total Stockholder Equity 5.64b)
RoCE = 12.15% (EBIT 1.28b / Capital Employed (Equity 5.64b + L.T.Debt 4.93b))
RoIC = 9.27% (NOPAT 1.02b / Invested Capital 11.0b)
WACC = 7.08% (E(96.4b)/V(102b) * Re(7.35%) + D(5.49b)/V(102b) * Rd(3.03%) * (1-Tc(0.21)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -1.56%
[DCF] Terminal Value 73.10% ; FCFF base≈3.06b ; Y1≈2.69b ; Y5≈2.17b
[DCF] Fair Price = 502.6 (EV 34.8b - Net Debt 3.97b = Equity 30.9b / Shares 61.4m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 76.71 | EPS CAGR: 29.03% | SUE: 0.02 | # QB: 0
Revenue Correlation: -64.22 | Revenue CAGR: -17.47% | SUE: -0.69 | # QB: 0
EPS current Quarter (2026-06-30): EPS=21.73 | Chg30d=-7.53% | Revisions=+14% | Analysts=4
EPS next Quarter (2026-09-30): EPS=20.18 | Chg30d=-17.20% | Revisions=-14% | Analysts=4
EPS current Year (2026-12-31): EPS=73.66 | Chg30d=-0.58% | Revisions=-14% | GrowthEPS=-34.2% | GrowthRev=+17.6%
EPS next Year (2027-12-31): EPS=105.78 | Chg30d=-1.90% | Revisions=-29% | GrowthEPS=+43.6% | GrowthRev=+17.2%
[Analyst] Revisions Ratio: -29%